These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 17374809)

  • 1. Treatment of men with lower urinary tract symptoms and overactive bladder.
    Young JG; Subramonian K
    JAMA; 2007 Mar; 297(11):1192-3; author reply 1193. PubMed ID: 17374809
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of men with lower urinary tract symptoms and overactive bladder.
    Bell WA; Amarshi N
    JAMA; 2007 Mar; 297(11):1192; author reply 1193. PubMed ID: 17374810
    [No Abstract]   [Full Text] [Related]  

  • 3. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial.
    Kaplan SA; Roehrborn CG; Rovner ES; Carlsson M; Bavendam T; Guan Z
    JAMA; 2006 Nov; 296(19):2319-28. PubMed ID: 17105794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service.
    Warner JL
    BJU Int; 2010 Aug; 106(4):586. PubMed ID: 20653664
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.
    Roehrborn CG; Kaplan SA; Kraus SR; Wang JT; Bavendam T; Guan Z
    Urology; 2008 Nov; 72(5):1061-7; discussion 1067. PubMed ID: 18817961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PHARMAC responds on tolterodine for overactive bladder.
    Moodie P
    N Z Med J; 2005 Feb; 119(1229):U1871. PubMed ID: 16498471
    [No Abstract]   [Full Text] [Related]  

  • 7. Editorial comment on: Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers.
    Speakman MJ
    Eur Urol; 2009 Sep; 56(3):542-3. PubMed ID: 19070420
    [No Abstract]   [Full Text] [Related]  

  • 8. Editorial comment on: Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers.
    Dmochowski R
    Eur Urol; 2009 Sep; 56(3):542. PubMed ID: 19070419
    [No Abstract]   [Full Text] [Related]  

  • 9. Editorial comment on: Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size.
    Wyndaele JJ
    Eur Urol; 2009 Feb; 55(2):481. PubMed ID: 18583023
    [No Abstract]   [Full Text] [Related]  

  • 10. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
    Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z
    BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms.
    Rovner ES; Kreder K; Sussman DO; Kaplan SA; Carlsson M; Bavendam T; Guan Z
    J Urol; 2008 Sep; 180(3):1034-41. PubMed ID: 18639297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost effectiveness of fesoterodine and tolterodine for the treatment of overactive bladder with urge urinary incontinence in Spain and Finland.
    Angulo JC; Valpas A; Rejas J; Linden K; Kvasz M; Snedecor SJ
    Clin Drug Investig; 2014 May; 34(5):297-307. PubMed ID: 24567280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Editorial comment on: Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size.
    Porru D
    Eur Urol; 2009 Feb; 55(2):480. PubMed ID: 18583021
    [No Abstract]   [Full Text] [Related]  

  • 14. Re: Cost-effectiveness of percutaneous tibial nerve stimulation versus extended release tolterodine for overactive bladder: H. W. Chen, R. S. Bercik, E. F. Werner And S. F. Thung; J Urol 2012; 187: 178-184.
    Kaufman RP
    J Urol; 2012 Dec; 188(6):2442; author reply 2443. PubMed ID: 23088965
    [No Abstract]   [Full Text] [Related]  

  • 15. Cost-effectiveness of percutaneous tibial nerve stimulation versus extended release tolterodine for overactive bladder.
    Chen HW; Bercik RS; Werner EF; Thung SF
    J Urol; 2012 Jan; 187(1):178-84. PubMed ID: 22100006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patients with overactive bladders deserve better.
    Brenner B; Rice M
    N Z Med J; 2006 Feb; 119(1229):U1846. PubMed ID: 16498474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Tolterodine tartrate combined with alpha-receptor blocker for benign prostatic hyperplasia with detrusor overactivity].
    Gan W; Zhang SF; Jia HT; Xie S; Luo MH; Li YF
    Zhonghua Nan Ke Xue; 2011 Apr; 17(4):348-50. PubMed ID: 21548214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolterodine for the treatment of urge urinary incontinence.
    Elterman DS; Chughtai B; Kaplan SA; Barkin J
    Expert Opin Pharmacother; 2013 Oct; 14(14):1987-91. PubMed ID: 23885788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overactive bladder disease: the urge for better therapies.
    Thomas L; Culley EJ
    J Manag Care Pharm; 2008 May; 14(4):381-6. PubMed ID: 18500915
    [No Abstract]   [Full Text] [Related]  

  • 20. Cost-effectiveness analysis of extended-release formulations of oxybutynin and tolterodine for the management of urge incontinence.
    Hughes DA; Dubois D
    Pharmacoeconomics; 2004; 22(16):1047-59. PubMed ID: 15524493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.